Mayumi H, Good R A
Division of Cardiovascular Surgery, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
J Exp Med. 1989 Jan 1;169(1):213-38. doi: 10.1084/jem.169.1.213.
A new method of cyclophosphamide (CP)-induced skin allograft tolerance in mice that can regularly overcome fully allogeneic (major H-2 plus non-H-2) antigen barriers in mice has been established. The components of the method are intravenous or intraperitoneal administration of 50-100 micrograms of anti-Thy-1.2 mAb on day -1, intravenous injection of 90 x 10(6) allogeneic spleen cells mixed with 30 x 10(6) allogeneic bone marrow cells from the same donor on day 0, and intraperitoneal injection of 200 mg/kg CP on day 2. In each of four fully allogeneic donor----recipient combinations, including C3H/HeJ (C3H; H-2k)----C57BL/6J(B6; H-2b), B6----C3H, BALB/cByJ (BALB; H-2d)----B6, and BALB----C3H, long-lasting survival of skin allografts was induced in most of the recipient mice. The specific tolerant state induced was dependent on the doses of the antibody and bone marrow cells used. The optimal timing of CP treatment to induce tolerance was found to be 1-3 d after the stimulating cell injection. Treatment with the anti-Thy-1.2 antibody together with CP on day 2 after the cell injection on day 0 also induced profound tolerance. In the B6 mice made tolerant of C3H with antibody, C3H spleen cells plus C3H bone marrow cells, and then CP, a minimal degree of stable mixed chimerism was established and the antitolerogen (C3H) immune responses examined here, including delayed footpad reaction (DFR), CTL activity, and capacity for antibody production against donor-strain antigens were abrogated in a tolerogen-specific manner. From cell transfer experiments, the mechanism of tolerance could be largely attributed to reduction of effector T cells reactive against the tolerogen, and strong suppressive influences that might prolong skin allograft survival directly were not detected in the tolerant mice. Moreover, pretreatment with anti-Thy-1.2 antibody or anti-L3T4 (CD4) antibody was more effective than pretreatment with anti-Lyt-1 (CD5) antibody or anti-Lyt-2 (CD8) antibody as an initial step in tolerance induction. These results suggest that permanent tolerance to fully allogeneic skin grafts may be induced because antibody given before the stimulating cell injection reduces the number of reactive T cells in the recipient mice. This antibody treatment may facilitate an antigen-stimulated destruction of responding and thus proliferating cells with CP by preventing a possibly less proliferative, more rapid maturation of reactive T cells or by destroying residual effector T cells.(ABSTRACT TRUNCATED AT 400 WORDS)
已建立一种环磷酰胺(CP)诱导小鼠皮肤同种异体移植耐受的新方法,该方法能定期克服小鼠完全异基因(主要组织相容性复合体H - 2加上非H - 2)抗原屏障。该方法的组成部分为:在第-1天静脉内或腹腔内给予50 - 100微克抗Thy - 1.2单克隆抗体;在第0天静脉注射90×10⁶个同种异体脾细胞与来自同一供体的30×10⁶个同种异体骨髓细胞的混合物;在第2天腹腔注射200毫克/千克CP。在四个完全异基因供体 - 受体组合中,包括C3H/HeJ(C3H;H - 2k)- C57BL/6J(B6;H - 2b)、B6 - C3H、BALB/cByJ(BALB;H - 2d)- B6和BALB - C3H,大多数受体小鼠的皮肤同种异体移植均诱导出长期存活。诱导的特异性耐受状态取决于所用抗体和骨髓细胞的剂量。发现诱导耐受的CP治疗最佳时机为刺激细胞注射后1 - 3天。在第0天细胞注射后第2天用抗Thy - 1.2抗体与CP联合治疗也诱导出深度耐受。在用抗体、C3H脾细胞加C3H骨髓细胞然后CP使B6小鼠对C3H产生耐受后,建立了最低程度的稳定混合嵌合体,在此检测的抗耐受原(C3H)免疫反应,包括迟发型足垫反应(DFR)、细胞毒性T淋巴细胞(CTL)活性以及针对供体品系抗原的抗体产生能力,均以耐受原特异性方式被消除。从细胞转移实验可知,耐受机制很大程度上可归因于针对耐受原的效应T细胞数量减少,且在耐受小鼠中未检测到可能直接延长皮肤同种异体移植存活的强烈抑制性影响。此外,作为耐受诱导的初始步骤,用抗Thy - 1.2抗体或抗L3T4(CD4)抗体预处理比用抗Lyt - 1(CD5)抗体或抗Lyt - 2(CD8)抗体预处理更有效。这些结果表明,可能因为在刺激细胞注射前给予抗体减少了受体小鼠中反应性T细胞的数量,从而诱导了对完全异基因皮肤移植的永久耐受。这种抗体治疗可能通过阻止反应性T细胞可能较少的增殖、更快的成熟或通过破坏残留的效应T细胞,促进抗原刺激下用CP对反应性及增殖性细胞的破坏。(摘要截短于400字)